Stock Events

Hansa Biopharma AB 

$3.26
3
-$0.04-1.36% Thursday 17:25

Statistics

Day High
3.3
Day Low
3.22
52W High
6.6
52W Low
2.26
Volume
200
Avg. Volume
19
Mkt Cap
171.45M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AprExpected
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Next
-3.71
-3.59
-3.48
-3.36
Expected EPS
-3.36
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HNSBF. It's not an investment recommendation.

About

Biotechnology
Health Technology
Pharmaceuticals: Major
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
Show more...
CEO
Soeren Tulstrup
Employees
168
Country
SE
ISIN
SE0002148817
WKN
000A0M65T

Listings